Attached files
| file | filename |
|---|---|
| EX-32.0 - EX-32.0 - Aspira Women's Health Inc. | vrml-20191231xex32_0.htm |
| EX-31.2 - EX-31.2 - Aspira Women's Health Inc. | vrml-20191231xex31_2.htm |
| EX-31.1 - EX-31.1 - Aspira Women's Health Inc. | vrml-20191231xex31_1.htm |
| EX-21.0 - EX-21.0 - Aspira Women's Health Inc. | vrml-20191231xex21_0.htm |
| EX-10.22 - EX-10.22 - Aspira Women's Health Inc. | vrml-20191231xex10_22.htm |
| EX-4.5 - EX-4.5 - Aspira Women's Health Inc. | vrml-20191231xex4_5.htm |
| EX-4.4 - EX-4.4 - Aspira Women's Health Inc. | vrml-20191231xex4_4.htm |
| EX-4.10 - EX-4.10 - Aspira Women's Health Inc. | vrml-20191231xex4_10.htm |
| 10-K - 10-K - Aspira Women's Health Inc. | vrml-20191231x10k.htm |
Consent of Independent Registered Public Accounting Firm
Vermillion, Inc.
Austin, Texas
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-106434, 333-109556, 333-139416, 333-189929, 333-202032, 333-217249 and 333-221092) and Form S-8 (Nos. 333-167204, 333-193312, 333-205855, 333-226462 and 333-232541) of Vermillion, Inc. of our report dated April 7, 2020, relating to the consolidated financial statements, which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
Austin, Texas
April 7, 2020